MX2019008292A - Composiciones probioticas y usos de las mismas. - Google Patents

Composiciones probioticas y usos de las mismas.

Info

Publication number
MX2019008292A
MX2019008292A MX2019008292A MX2019008292A MX2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A MX 2019008292 A MX2019008292 A MX 2019008292A
Authority
MX
Mexico
Prior art keywords
lactobacillus
probiotic compositions
dsm
prevention
treatment
Prior art date
Application number
MX2019008292A
Other languages
English (en)
Inventor
Lazou Ahrén Irini
AGARDH Daniel
Niklas Larsson Lars
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by Probi Ab filed Critical Probi Ab
Publication of MX2019008292A publication Critical patent/MX2019008292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La presente invención se refiere a al menos una cepa probiótica de Lactobacillus para su uso en un sujeto para la prevención y/o el tratamiento de la autoinmunidad de la enfermedad celiaca (AEC), o para su uso en prevención y/o tratamiento de la enfermedad celíaca (CD).Una composición preferida para su uso de acuerdo con la invención es una composición que comprende una combinación de Lactobacillus paracasei y Lactobacillus plantarum, especialmente L. paracasei 8700:2 (DSM 13434) en combinación con L. plantarum HEAL 9 (DSM 15312).
MX2019008292A 2017-01-12 2018-01-12 Composiciones probioticas y usos de las mismas. MX2019008292A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof
PCT/EP2018/050789 WO2018130667A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2019008292A true MX2019008292A (es) 2019-09-16

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008292A MX2019008292A (es) 2017-01-12 2018-01-12 Composiciones probioticas y usos de las mismas.

Country Status (14)

Country Link
US (1) US11166993B2 (es)
EP (1) EP3568144B1 (es)
JP (1) JP7089523B2 (es)
KR (1) KR102500496B1 (es)
CN (1) CN110177561B (es)
AU (1) AU2018207946A1 (es)
BR (1) BR112019014418A2 (es)
CA (1) CA3049624A1 (es)
CL (1) CL2019001938A1 (es)
MX (1) MX2019008292A (es)
MY (1) MY195253A (es)
PH (1) PH12019501629A1 (es)
RU (1) RU2763311C2 (es)
WO (1) WO2018130667A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
WO2007040446A1 (en) 2005-10-06 2007-04-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
CN101384269B (zh) * 2005-10-06 2012-11-14 普罗比公司 乳酸杆菌用于治疗病毒感染的用途
PL1996696T3 (pl) 2006-03-17 2017-08-31 Probi Aktiebolag Termostabilne szczepy Lactobacillus
WO2007108763A1 (en) 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
ES2549481T3 (es) 2008-11-30 2015-10-28 Immusant, Inc. Composiciones y métodos para el tratamiento de enfermedad celíaca
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
CA2876963C (en) 2012-06-18 2021-07-06 H.J. Heinz Company Gluten-related disorders
ES2804615T3 (es) * 2013-04-03 2021-02-08 Probi Ab Cepas probióticas para su uso en el tratamiento o la prevención de la osteoporosis
ES2764210T3 (es) * 2014-11-25 2020-06-02 Dsm Ip Assets Bv Lactobacillus para usar como probiótico

Also Published As

Publication number Publication date
US20190358275A1 (en) 2019-11-28
CA3049624A1 (en) 2018-07-19
KR102500496B1 (ko) 2023-02-16
MY195253A (en) 2023-01-11
CL2019001938A1 (es) 2019-09-27
EP3568144B1 (en) 2024-05-08
RU2763311C2 (ru) 2021-12-28
CN110177561A (zh) 2019-08-27
JP2020513780A (ja) 2020-05-21
CN110177561B (zh) 2023-09-12
BR112019014418A2 (pt) 2020-04-14
JP7089523B2 (ja) 2022-06-22
US11166993B2 (en) 2021-11-09
EP3568144A1 (en) 2019-11-20
WO2018130667A1 (en) 2018-07-19
PH12019501629A1 (en) 2020-06-01
AU2018207946A1 (en) 2019-07-25
RU2019121145A (ru) 2021-02-12
RU2019121145A3 (es) 2021-04-26
KR20190104568A (ko) 2019-09-10

Similar Documents

Publication Publication Date Title
EP4086336A4 (en) STRAIN OF LACTOBACILLUS PLANTARUM, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES CONTAINING SAME
MY160508A (en) Lactobacillus plantarum strains as hypocholesterolemic agents
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
NZ712959A (en) Probiotic strains for use in treatment or prevention of osteoporosis
MX346458B (es) Composicion probiotica para la salud bucal.
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2020013439A (es) Composiciones probioticas y usos de las mismas.
SA113340703B1 (ar) سلالة جديدة من بكتيريا Lactobacillus Crispatus
BR112019001116A2 (pt) composição probiótica usada no tratamento e/ou prevenção da dermatite atópica
EP4086334A4 (en) LACTOBACILLUS FERMENTUM STRAIN AND COMPOSITION THEREOF FOR PREVENTING OR TREATING METABOLIC DISEASES
MX2021009398A (es) Composiciones probioticas que comprenden cepas de lactobacillus reuteri y metodos de uso.
EE05799B1 (et) Hüpokolestereemilist probiootilist mikroorganismi tüve Lactobacillus plantarum Inducia DSM 21379 sisaldav kompositsioon kasutamiseks südame-veresoonkonnahaiguste ennetamiseks
EP4086335A4 (en) LACTOBACILLUS FERMENTUM STRAIN, AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC DISEASES, INCLUDING THE SAME
MX2016014991A (es) Composiciones que contienen acido borico y una mezcla de lactobacilos.
WO2020091179A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물
WO2020008149A8 (fr) Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin
PH12017502042A1 (en) Dietary supplement
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
MX2017007654A (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas.
MX2021012676A (es) Composiciones probioticas y usos de las mismas.
GEP20207089B (en) Histamine-producing bacterial strains and their use in cancer
AU2019263623A8 (en) Probiotic Bifidobacterium breve strain and compositions comprising said strain
EP3757207A4 (en) Bifidobacterium lungum rapo strain for alleviation, prevention, or treatment of rheumatoid arthritis and composition comprising same
WO2020091180A3 (ko) 프로바이오틱스를 유효 성분으로 포함하는 이차성 골다공증의 예방 또는 치료용 조성물